Clinical Value and Efficacy Index of Lymphadenectomy for Thoracic Escc
NCT ID: NCT05604664
Last Updated: 2022-11-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1727 participants
OBSERVATIONAL
2022-05-01
2022-10-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* provide a basis for accurate staging and the relationship between OS and lymph node dissection
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Impact of Two-field or Three-field Lymphadenectomy on Overall Survival in Middle and Lower Thoracic Esophageal Squamous Cell Carcinoma: An Observational Study
NCT05617352
Precisely Estimation of the Prognostic Value of Lymph Node in ESCC
NCT04764240
Two-field Versus Three-field Lymph Node Dissection in ESCC After Neoadjuvant Therapy
NCT05420480
RESECTED LYMPH NODES AND SURVIVAL OF PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA: AN OBSERVATIONAL STUDY
NCT05570487
The Prognostic Value of Tertiary Lymphatic Structure in Esophageal Squamous Cell Carcinoma
NCT06241066
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Underwent esophagecomy (two-field or three-field LN dissection)
3. The primary tumor was thoracic ESCC
Exclusion Criteria
2. Patients underwent salvage or R1/R2 esophagecomy
3. The number of resected lymph nodes (RLNs) less than 15
4. With neoadjuvant therapy(NT) or salvage chemoradiotherapy(SCRT)
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yongtao Han
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yongtao Han
Clinical Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sichuan Cancer Hospital and Research Institute
Chengdu, Sichuan, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SCCH-TS2203
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.